替格瑞洛联合溶栓治疗合并2型糖尿病的急性STEMI患者近期疗效及其对炎性因子水平的影响

doi:10.3969/j.issn.1671-7171.2018.01.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the short term efficacy of ticagrelor combined with thrombolytic therapy for patients with ST-segment elevation myocardial infarction (STEMI) complicated with type 2 diabetes and its effects on level of inflammatory factors.【Methods】A total of 70 acute STEMI patients with type 2 diabetes, who underwent thrombolytic therapy in our hospital from February 2015 to February 2017, were randomly divided into the ticagrelor group (n=35) and the clopidogrel group (n=35) according to the random number table method. Both groups were given aspirin anti-platelet aggregation and other conventional treatment. In addition, the ticagrelor group was given ticagrelor and urokinase, while the clopidogrel group was given clopidogrel and urokinase The total clinical effective rate and the percentage of ST segment regression >50% after 1h and 2h thrombolysis were compared between the two groups. The levels of High sensitive C reactive protein (hs-CRP) and interleukin-6 (IL-6) before and 1d, 3d, 7d after treatment were detected. The incidence of recurrent myocardial infarction within 1 week, as well as the left ventricular end diastolic diameter (LVEDD)and left ventricular ejection fraction (LVEF)after 1 week were recorded.【Results】There were no significant differences in serum hs-CRP and IL-6 levels between the two groups before treatment (P> 0.05). The levels of hs-CRP and IL-6 in both groups were significantly lower at 1, 3 and 7 days after treatment compared to before treatment. Hs-CRP and IL-6 level changes in the ticagrelor group were significantly lower than those in the clopidogrel group; the difference was statistically significant (P <0.05). The total effective rates of the ticagrelor group were 80.0% (28/35) and 94.3% (33/35) after thrombolysis for 1and 2 h, respectively, which were significantly higher than those of the clopidogrel group 71.5% (25/35)and 88.6% (31/35), respectively; the differences were statistically significant (P<0.05).The percentage of ST segment regression >50% after 1h and 2h thrombolysis in the ticagrelor group were 74.3% and 97.1%, respectively, which were significant higher than those in the clopidogrel group 62.9%and 91.4%, respectively;those of the ticagrelor group were higher than the clopidogrel group (P<0.05). After 1 week of treatment, the LVEDD in the ticagrelor group was significantly lower than that in clopidogrel group (45.2 ± 3.4) mm vs (50.3 ± 3.9) mm, and the LVEF in the ticagrelor group was significantly higher than that in the clopidogrel group (62.8±4.2)% vs (55.2 ± 3.8)%; the difference was statistically significant (P <0.05). The incidence of reccurrent infarction within 1 week in the ticagrelor group was 0.0%, while the incidence in the clopidogrel group was 5.7% (2/35); the difference was statistically significant (P<0.05).【Conclusion】The short term efficacy of ticagrelor combined with thrombolytic therapy for patients with STEMI complicated with type 2 diabetes is good. The treatment significantly improves the success rate of thrombolysis and cardiac function, reduces inflammatory factors after myocardial infarction and the rate of recurrent myocardial infarctions.

Key words： Platelet Aggregation Inhibitors/TU Thrombolytic Therapy Myocardial Infarction/CO Acute Disease Diabetes Mellitus, Type 2/CO Interleukin-6

Received: 09 May 2017

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YOU San-li
	WANG Zhao

Cite this article:

YOU San-li,WANG Zhao. Short Term Efficacy of Ticagrelor Combined with Thrombolytic Therapy for Patients with ST-segment Elevation Myocardial Infarction(STEMI) Complicated with Type 2 Diabetes and Its Effects on Level of Inflammatory Factors[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(1): 22-25.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.01.007 OR http://www.jcr.net.cn/EN/Y2018/V35/I1/22

[1] Olivier CB,Schnabel K,Weber S,et al.Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel[J].J Thromb Thrombolysis,2016,42(1):84-89.
[2] 黄坚,孔小明,陆士奇,等.替格瑞洛治疗非ST段抬高型急性冠脉综合征的疗效[J].中国老年学,2014,v.34(16):4438-4439.
[3] 丁艳萍,符红军,杨静萍,等.替格瑞洛和氯吡格雷对急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后炎性因子的影响[J].临床合理用药杂志,2017,10(3):3-6.
[4] 国家卫生计生委合理用药专家委员会;中国药师协会.急性ST段抬高型心肌梗死溶栓治疗的合理用药指南[J].中国医学前沿杂志电子版,2016,8(8):25-41.
[5] 急性ST段抬高心肌梗死溶栓治疗中国专家共识组.急性ST段抬高心肌梗死溶栓治疗中国专家共识(2009年版)[J].中华内科杂志,2009,48(10):885-890.
[6] Viatte S,Plant D,Raychaudhuri S.Genetics and epigenetics of rheumatoid arthritis[J].Nat Rev Rheumatol,2013,9(3):141.
[7] 梁茜,杨希立,张健瑜,等.替格瑞洛对糖尿病合并急性冠脉综合征患者冠状动脉介入治疗术后炎性因子水平的影响研究[J].中国全科医学,2016,19(7):799-802.
[8] 王胜强,李震,王晓刚,等.高负荷剂量的国产氯吡格雷在急性心肌梗死急诊冠脉介入治疗中的效果观察[J].山东医药,2012,52(29):74-75.
[9] Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2011,32 (23): 2999-3054.
[10] Herman JG,Graff JR,Myhnen S,et al.Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands[J].Proc Natl Acad Sci USA,1996,93(18):9821-9826.
[11] Teng R,Mitchell PD,Butler K.Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers[J].J Clin Pharm Ther,2012,37(4):464.
[12] Butler K,Teng R.Pharmacokinetics,pharmacodynamics,safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers[J].Br J Clin Pharmacol,2010,70(1):65-77.